FOI 23/249 – Pluserix MMR

MHRA RESPONSE
22 June 2023

Dear

Thank you for your email where you requested the following information:
(a) Was the licensing of Pluserix MMR progressed under the Clinical Trial Exemption Scheme (11th march 1981)?
(b) Was Pluserix MMR provided with a Clinical Trial Exemption Certificate?

Our Healthcare Quality and Access group have checked our archive, including paper records we hold, and can confirm that we hold no information that answers the above questions.

If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

We apologise for delay in responding.

Yours sincerely

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency